Canaccord Genuity Reiterates Buy Rating, $22 PT on Cytokinetics on CK357 Potential

In a report published Wednesday, Canaccord Genuity analyst Ritu Baral reiterated a Buy rating and $22.00 price target on Cytokinetics CYTK. In the report, Canaccord Genuity noted, “Reiterate BUY; $22 target on potential of CK357 in ALS and AMGN-partnered omecamtiv in heart failure. We think CK357 (tirasemtiv) Phase 1/2 proof-of-concept data in ALS shows unique (if early) efficacy potential. Ph2 data due Q4/13 could be a key catalyst. We also think recent developments point to the early Sept. Ph2 ATOMIC data being positive, which could also be a strong catalyst. Our $22 price target is based on a pNPV analysis.” Cytokinetics closed on Tuesday at $12.05.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsCanaccord GenuityRitu Baral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!